Cure Alzheimer's Fund: Targeting Breakthrough Research

(October 29, 2012) (PRWEB) October 30, 2012 -- The Brain Research Foundation (BRF) today announced that the 2012 recipients of the Frederic A. Gibbs Discovery Award will be Michael W. Ferro Jr. and David M. Holtzman, M.D.

Largest Single Private Investment in Alzheimer’s Whole Genome Sequencing Targets Effective Therapies and Cure: $5.4 Million Awarded for Research to Guide Alzheimer’s Drug Development

Understanding who is most susceptible to Alzheimer’s disease and developing early detection models, effective therapies and possibly a cure, is the goal of the largest single private scientific grant ever invested in Alzheimer’s Whole Genome Sequencing (WGS) focused on families afflicted with the disease.

Cure Alzheimer's Fund co-founder & chairman, Jeff Morby, and lead scientist, Rudy Tanzi, Ph.D., discussed current developments in Alzheimer's research and the coming Alzheimer's tsunami on WCAI Cape & Islands NPR Station on August 23rd. Listen at The Point with Mindy Todd.

A new study of an existing drug for immune disorders that may have positive effects for Alzheimer’s patients has attracted national attention lately. While phase III clinical trial results for Gammagard, an IVIG or “intravenous immunoglobulin therapy” by Baxter International are not expected until early 2013, hope for success must be balanced with a hard look at the data. The Wall Street Journal’s story on this drug and the prognosis for success by Dr.

It was announced yesterday that Bapineuzumab, the Abeta immunotherapy drug, failed to meet cognitive and functional goals in a late stage trial of Alzheimer's patients who carry the APOE4 variant. “There was no reason to believe, unless there was a miracle, that this would be positive. It will only be the results of the non-APOE4 carriers that will inform us about the future [of bapineuzumab].”  said Rudolph Tanzi, Joseph P. and Rose F.

Cure Alzheimer’s Fund is pleased to salute Massachusetts General Hospital for placing number 1 in the current issue of U.S. News and World Report’s “Best Hospital” survey. While Cure Alzheimer’s Fund has supported more than 24 leading Alzheimer’s research institutions since its inception in 2004, Mass General has received almost $10 million in research grants from Cure Alzheimer’s Fund during that time.

The New York Times Magazine appearing on Sunday, June 10, 2012, and available now online, carries a powerful narrative of a family’s journey through the tragedy of early-onset Alzheimer’s.

Bobby Zerwick left his comfortable home in Pennsylvania last March 10 with two goals: To hike the entire Appalachian Trail this summer and to raise much-needed research funds to find a cure for Alzheimer’s disease. The hike started at Springer Mountain in Georgia, and Bobby will hike north for a total of about five months. His journey will be completed this late summer or early fall when he reaches Mount Katahdin in Maine, having traveled more than 2,175 miles.

THE COMING ALZHEIMER’S TSUNAMI: Society’s Next Big Challenge

Given the worldwide concern about Alzheimer’s disease, Mr. Kalyan Banerjee, president of Rotary International, invited Cure Alzheimer’s Fund to present at the Rotary Club’s Annual Conference in Bangkok, Thailand, on May 9, 2012.

A new study, led by Cure Alzheimer’s Fund grant recipient Lee E. Goldstein, MD, Ph.D., of Boston University School of Medicine and co-authored by multiple researchers, including Cure Alzheimer's Fund Research Consortium chairman Rudy Tanzi, Ph.D., and Cure Alzheimer's Fund grant recipient Rob Moir, Ph.D., has found that war veterans who experience brain injuries from blast explosions are at risk for later developing neurological disease. This research was covered in multiple news outlets, including The New York Times.

From the article: